Alaunos Therapeutics
TCRT
148 hedge funds and large institutions have $65.9M invested in Alaunos Therapeutics in 2022 Q1 according to their latest regulatory filings, with 17 funds opening new positions, 31 increasing their positions, 41 reducing their positions, and 33 closing their positions.
2,587% more call options, than puts
Call options by funds: $5.45M | Put options by funds: $203K
0.13% less ownership
Funds ownership: 0.44% → 0.31% (-0.13%)
10% less funds holding
Funds holding: 165 → 148 (-17)
24% less repeat investments, than reductions
Existing positions increased: 31 | Existing positions reduced: 41
48% less first-time investments, than exits
New positions opened: 17 | Existing positions closed: 33
58% less capital invested
Capital invested by funds: $156M → $65.9M (-$90M)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Goldman Sachs
New York
|
+$3.48M |
| 2 |
Nuveen
Charlotte,
North Carolina
|
+$649K |
| 3 |
DCM
Discovery Capital Management
South Norwalk,
Connecticut
|
+$570K |
| 4 |
Renaissance Technologies
New York
|
+$387K |
| 5 |
GCP
GSA Capital Partners
London,
United Kingdom
|
+$199K |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
MP
MSD Partners
New York
|
-$25.9M |
| 2 |
State Street
Boston,
Massachusetts
|
-$6.93M |
| 3 |
Millennium Management
New York
|
-$1.15M |
| 4 |
Rafferty Asset Management
New York
|
-$889K |
| 5 |
Wellington Management Group
Boston,
Massachusetts
|
-$824K |
TCRT Hedge Fund Activity: Q1 2022 in Review
148 of the 6,360 institutional investors tracked by Wall St. Rank reported a position in Alaunos Therapeutics (TCRT) for Q1 2022, worth a combined $65.9M — down 58% from $156M a quarter earlier.
Sellers outnumbered buyers: 33 funds closed out of TCRT and 17 opened new positions — a net loss of 16 holders — while 41 trimmed existing stakes and 31 added.
The largest buyer was Goldman Sachs, adding an estimated $3.48M. The largest seller was MSD Partners, cutting an estimated $25.9M.
- 148 institutional investors held Alaunos Therapeutics (TCRT) as of Q1 2022, down from 165 in Q4 2021.
- Funds reported $65.9M of Alaunos Therapeutics stock for Q1 2022, down 58% quarter-over-quarter.
- 17 funds opened new Alaunos Therapeutics positions in Q1 2022 and 33 closed out, a net change of -16 holders.
- The largest Alaunos Therapeutics buyer in Q1 2022 was Goldman Sachs, an estimated $3.48M added.
- The largest Alaunos Therapeutics seller in Q1 2022 was MSD Partners, an estimated $25.9M sold.
Based on aggregated 13F filings for Q1 2022.